The Association of the British Pharmaceutical Industry says it supports the UK government’s bid to “tackle excessive profiteering” through the newly passed Health Service Medical Supplies (Costs) Act. The ABPI has welcomed amendments that were made to the draft version of the act that ensure the powers detailed in the legislation are “proportionate”.
The Health Service Medical Supplies (Costs) Act received Royal Assent from the House of Commons on April 27. It aims...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?